Does the combination of an α1-adrenergic antagonist with a 5α-reductase inhibitor improve urinary symptoms more than either monotherapy?

Current Opinion in Urology

Volumn 20, Issue 1, 2010, Pages 1-6

  Hollingsworth, John M ^a,b   Wei, John T ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adrenergic a antagonists, drug therapy; Prostatic hyperplasia; Testosterone 5 reductase inhibitors; Treatment outcome

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTENONE 5ALPHA REDUCTASE;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LOWER URINARY TRACT SYMPTOM; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; URINE FLOW RATE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; MALE; PROSTATISM; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DRUG THERAPY, COMBINATION; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATISM;

EID: 74549225595     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283336f96     Document Type: Article

References (28)

1. Wilensky GR. The policies and politics of creating a comparative clinical effectiveness research center. Health Aff (Millwood) 2009; 28:w719-w729.
2. Congressional Budget Office. The long-term outlook for healthcare spending. Washington, DC: Congressional Budget Office; 2007.
3. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995; 155:477-481
4. Goluboff ET, Olsson CA. Urologists on a tightrope: coping with a changing economy. J Urol 1994; 151:1-4.
5. Gee WF, Holtgrewe HL, Albertsen PC, et al. Subspecialization, recruitment and retirement trends of American urologists. J Urol 1998; 159:509-511.
6. Drug topics: the newsmagazine for pharmacists. http://durgtopics. modernmedicine. com/. [Accessed 1 August 2009].
7. Kawabe K. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 1995; 76 (Suppl 7):63-67.
8. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48:406-415.
9. Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996; 47:159-168. (Pubitemid 26075268)
10. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 2001; 58:953-959.
11. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557-563.
12. Brawer MK, Lin DW, Williford WO, et al. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative study #359. Prostate 1999; 39:234-239.
13. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175:1422-1426.
14. Johnson TM, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003; 170:145-148.
15. Johnson TM, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007; 178:2045-2050.
16. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006; 175:217-220.
17. Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial [see comment]. J Urol 2008; 180:1030-1032.
18. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998; 160:1358-1367.
19. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44:461-466.
20. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34:169-175.
21. Kuo HC. Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia. Urol Int 1998; 60:85-91.
22. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58:203-209.
23. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179:616-621.
24. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
25. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61:119-126.
26. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533-539.
27. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial 1996; 17:1-12.
28. Moher D, Pham B, Klassen TP, et al. Does the language of publication of reports of randomized trials influence the estimates of intervention effectiveness reported in meta-analyses? Syst Rev Evid Action Int Cochrane Colloq 6th 1998 Baltim Md 1998; 6:70.